Today at #ASCO2024: Our positive Phase 2 clinical and biomarker results with ST101 in GBM were presented during an oral presentation by Dr. Fabio M. Iwamoto, MD, Principal Investigator of the ST101-101 clinical study. The Phase 2 data demonstrates durable responses with ST101 across 3 cohorts of patients with recurrent and newly diagnosed GBM, and supports its continued clinical development as a backbone treatment in combination with standard-of-care and immune-oncology agents. Learn more about these promising results here: https://lnkd.in/g_V2RPzv #ASCO24 #oncology #GBM
Sapience Therapeutics, Inc.’s Post
More Relevant Posts
-
Product Management | Content Development | Patient-Reported Outcomes | Oncology Research | Clinical Safety & Effectiveness
It’s true 💫 I need your tips for favorite #ONSCongress events and Capitol City must-do’s! 🌸 And I want to hear about your experiences with ePROs and remote symptom monitoring! 🖥️📲 #remotesymptommonitoring #continuoustemperaturemonitoring #epros #patientexperience #healthcareinnovation #oncology #innovativecollaboration #cancercare #technologyinoncology
Blue Spark Technologies joins Carevīve at ONS Congress 2024! 👏 We are thrilled to share our recent collaboration with Blue Spark Technologies and Carevīve at #ONSCongress 2024 in Washington, D.C.! Delve into the advantages and hurdles of remote symptom monitoring innovations like continuous temperature monitoring and ePROs for oncology patients and providers. Don't miss this insightful poster session on April 27th; learn more and connect with Ruth Phillips and April Boyd. #remotesymptommonitoring #continuoustemperaturemonitoring #epros #patientexperience #healthcareinnovation #oncology #innovativecollaboration #cancercare
To view or add a comment, sign in
-
Panavance is dedicated to addressing #cancer types that are difficult to treat with a clear unmet need. Our lead therapeutic, misetionamide (GP-2250) is now in a Phase 1 trial to investigate the safety, tolerability, and preliminary antitumor activity in combination with standard of care treatment for patients with #pancreaticcancer. Learn more about what sets GP-2250 apart: https://lnkd.in/e2g_RsyP #oncology
To view or add a comment, sign in
-
Prof Dr Natalia Valdiviezo Lama shares the post-progression results of the pivotal FLAURA-2 trial. In addition to significantly delaying disease progression, adding chemotherapy to first line osimertinib also significantly improves the time to the first and subsequent line of therapy and delays the progression free survival on the first subsequent line of therapy in patients with EGFR-mutant metastatic NSCLC. Discover these vital insights. 👇 For all ELCC 2024 videos, find the link in the comments! #MediMix #ELCC2024 #LungCancer #OncologyInnovation
To view or add a comment, sign in
-
Love these programs - distilling the important #NSCLC data from #ASCO2024 and discussing clinical implications. Feel free to share with anyone who may need this Supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. #ASCO #ASCO24 #ASCO2024 #NSCLC #NSCLCASCO #EVOKE1trial #CROWNtrial #PALOMA3trial #lungcancer #oncology #oncologytraining #oncologyeducation #continuingmedicaleducation #cme #independentmedicaleducation #ime #SpringerIME
Just dropped! New Expert Perspectives video: ASCO 2024 Highlights Advances in NSCLC. Complete the post-activity assessment to claim your CME credits. Dr. Heather Wakelee and Dr. Julia Rotow delve into the clinical implications of recent studies presented at ASCO 2024 concerning non-small cell lung carcinoma (NSCLC). Their analysis covers the findings from the EVOKE-01, CROWN, and PALOMA-3 trials, among others, emphasizing how these results can be applied to enhance clinical practice and patient outcomes. Watch it now! Access the content and claim your CME credits at: https://lnkd.in/e2uTeBYC --- This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. #ASCO #ASCO24 #ASCO2024 #NSCLC #NSCLCASCO #EVOKE1trial #CROWNtrial #PALOMA3trial #lungcancer #oncology #oncologytraining #oncologyeducation #continuingmedicaleducation #cme #independentmedicaleducation #ime #SpringerIME
To view or add a comment, sign in
-
ESMO 2024 Quick Takes with LARVOL: Guru Sonpavde, MD In this post-ESMO 2024 Quick Take, Dr. Guru Sonpavde, MD, shares his insights on the practice-changing NIAGARA trial. This randomized phase 3 study, involving approximately 1,000 patients, evaluated neoadjuvant gemcitabine, cisplatin, with or without durvalumab for muscle-invasive bladder cancer. The results showed significant improvements in both event-free survival (hazard ratio: 0.68) and overall survival (hazard ratio: 0.75), signaling a major shift in treatment approaches. Stay tuned for more post-ESMO reflections and updates on how this trial may shape future clinical practice. #ESMO24 #CancerResearch #NIAGARATrial #LARVOLQuickTake
To view or add a comment, sign in
-
Just dropped! New Expert Perspectives video: ASCO 2024 Highlights Advances in NSCLC. Complete the post-activity assessment to claim your CME credits. Dr. Heather Wakelee and Dr. Julia Rotow delve into the clinical implications of recent studies presented at ASCO 2024 concerning non-small cell lung carcinoma (NSCLC). Their analysis covers the findings from the EVOKE-01, CROWN, and PALOMA-3 trials, among others, emphasizing how these results can be applied to enhance clinical practice and patient outcomes. Watch it now! Access the content and claim your CME credits at: https://lnkd.in/e2uTeBYC --- This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. #ASCO #ASCO24 #ASCO2024 #NSCLC #NSCLCASCO #EVOKE1trial #CROWNtrial #PALOMA3trial #lungcancer #oncology #oncologytraining #oncologyeducation #continuingmedicaleducation #cme #independentmedicaleducation #ime #SpringerIME
To view or add a comment, sign in
-
🔥 In-Depth Insight from ESMO 2024! Prof Dr Alexandra Drakaki presents findings from the VOLGA trial, which highlights plasma ctDNA as a promising predictive marker in MIBC. Neoadjuvant immunotherapy and targeted treatments improved outcomes in cisplatin-ineligible patients. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #MIBC #BladderCancer #Oncology #CancerResearch #ClinicalTrials
To view or add a comment, sign in
-
Phase 3 ADRIATIC Trial: Durvalumab greatly improved survival rates in limited-stage small-cell lung cancer patients after concurrent chemoradiation, extending overall survival to 55.9 months compared to 33.4 months with a placebo. At VieCure, we stay at the forefront of medical advancements by offering innovative clinical decision support. This enables oncologists to choose the most effective treatments, ensuring that every patient benefits from personalized, evidence-based care. Our dedication to enhancing patient outcomes remains unwavering. #VieCure #Oncology #PrecisionMedicine #LungCancerAwareness https://lnkd.in/gV7AVAQ5
To view or add a comment, sign in
-
📣 As March is #kidneycancer awareness month we wanted to share some NEW findings in #renalcellcarcinoma: Data from the CLEAR study, presented at #ASCOGU 2024 🇺🇸 🎥 Viktor Grünwald, MD, University Hospital Essen, discusses findings from the Phase III #CLEARtrial (NCT02811861) of #lenvatinib and #pembrolizumab in patients with advanced #renalcellcarcinoma (#aRCC) across varying baseline tumor sizes. 🌟 Regardless of tumor size, #lenvatinib and #pembrolizumab exhibited clinically-meaningful improvements in overall survival, progression-free survival, and objective response rate. These findings suggest the efficacy of #lenvatinib and #pembrolizumab as a first-line treatment across varying baseline tumor sizes. 🔎 To hear from Viktor Grünwald, MD, head to 👉 https://lnkd.in/eBQBAVH6 #Oncology #GUsm #kidneycancerawarenessmonth #VJOncology
To view or add a comment, sign in
-
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China Full Press Release Here: https://lnkd.in/gAvUNM_N #SummitTherapeutics #oncology #WCLC24 #IASLC #Ivonescimab
To view or add a comment, sign in
3,220 followers